A fourth COVID-19 vaccine candidate has gone into the final stage of clinical trials in the U.S., with Johnson & Johnson announcing the start of its Phase 3 trial Wednesday, NBC News reports.
The drugmaker follows Pfizer and Moderna, whose Phase 3 trials began in late July. AstraZeneca also started its Phase 3 vaccine trial this month, but it remains on pause in the U.S. after a participant in the U.K. was reported to have developed a spinal cord injury.
The Johnson & Johnson trial is not expected to yield preliminary results for at least two months.
Full coverage of the COVID-19 outbreak and how it impacts you and our communities
Read the full story on NBCNews.com